Navigation Links
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:2/1/2008

itigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase I clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements are
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
2. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
3. Amicus Therapeutics to Host R&D Day
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
7. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
8. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
9. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
10. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
11. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Strategic marketing and branding agency, Red ... Able&Co. , The agency was founded in 2008 by ... inception, continuing to expand its business each year. “We ... a core focus on branding and marketing strategy. As ... and visual identity to reflect who we have become ...
(Date:3/6/2015)... , March 6, 2015 According ... Market by Product (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, ... Skin, Dental, Vaginal, Breast augmentation) - Global Forecast to ... is expected to reach $14.7 Billion in 2019 from ... 7.5% from 2014 to 2019. Browse ...
(Date:3/6/2015)... , March 6, 2015  Attorney Advertising-- Bronstein, Gewirtz ... behalf of purchasers of the securities of Orexigen ... OREX -News).  Such investors are advised ... investor relations coordinator Eitan Kimelman at ... investigation concerns whether Orexigen and certain of its ...
(Date:3/6/2015)... March 6, 2015 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, announced today that it ... at 8:30 a.m. ET on Friday, March 13, 2015 ... financial results and provide a corporate update. ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2
... ... Inc. 5000 , ... Boston, MA (PRWEB) August 13, 2009 -- Inc. magazine announced on Wednesday its 2009 ... a diversified technology solutions company and a leader in web-database solutions, healthcare intelligence and ...
... National Physical Laboratory (NPL) in Teddington have developed imaging technology ... minimise wastage and solve an impending labour shortage for UK ... to 60% - which can mean up to 100,000 of ... farmers who were consulted during research. Falling number of migrant ...
... , , OMAHA, Neb., Aug. ... the quarter ended June 30, 2009. The Company,s financial results are presented in ... , The Company reported a net loss of $730,000 or $0.01 per ... $101,000 or $0.00 per share for the second quarter of 2008. , ...
Cached Biology Technology:Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies 2UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year 2Transgenomic, Inc. Reports Second Quarter 2009 Results 2Transgenomic, Inc. Reports Second Quarter 2009 Results 3Transgenomic, Inc. Reports Second Quarter 2009 Results 4Transgenomic, Inc. Reports Second Quarter 2009 Results 5Transgenomic, Inc. Reports Second Quarter 2009 Results 6Transgenomic, Inc. Reports Second Quarter 2009 Results 7Transgenomic, Inc. Reports Second Quarter 2009 Results 8
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... is available in German . , The hairs ... a 10 per cent decrease in fuel consumption. The plant has ... under water. Researchers at the University of Bonn, Rostock and Karlsruhe ... how the fern does this. Their results can possibly be used ...
... of the relationship between testosterone and natural selection ... defied some expectations and confirmed others. Scientists ... Indiana University-Purdue University Indianapolis, and the University of ... The American Naturalist (now online) that ...
... Scientists (AAPS) is a professional, scientific society of ... and other research institutes worldwide. Founded in 1986, ... exchange of knowledge among scientists to enhance their ... programs, on-going education, information resources, opportunities for networking, ...
Cached Biology News:Bionic coating could help ships to economize on fuel 2Natural selection for moderate testosterone surprises scientists 2Natural selection for moderate testosterone surprises scientists 3Natural selection for moderate testosterone surprises scientists 4
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
Biology Products: